Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Nov 27;15:1491808. doi: 10.3389/fimmu.2024.1491808

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Zhu, Xiao, Hou, Huang, Xu, Guo, Dong, Xu, Zhang and Gu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The relationships between the risk score and the tumor immunotherapy and chemotherapeutic sensitivity. (A) The TIDE scores between the high- and low-risk groups. (B) The proportion of BLCA patients with response to immunotherapy in two risk groups in the IMvigor210 cohort. (C) Survival analyses for BLCA patients with high or low risk score in the IMvigor210 cohort. (D) Differences in risk scores between the responders and non-responders in the IMvigor210 cohort. (E-H) Differences in the IPS between high- and low-risk groups stratified by CTLA4 and PD-1. (I-P) Relationships between the risk score and the chemotherapeutic sensitivity. TIDE, tumor immune dysfunction and exclusion; BLCA, bladder cancer. IPS, immunophenoscore.